Cell & Gene: The Podcast

We love to hear from our listeners. Send us a message.Rare Disease Day is February 29, 2024, and in honor of this important day, Cell & Gene: The Podcast Host Erin Harris sits down with Jackson Laboratory’s (JAX) Rare Disease Translational Center (RDTC)'s VP, Cat Lutz. They discuss RDTC's mission, the specific qualifications that make up a rare disease, how the study of rare diseases can potentially advance progress in common diseases, and much more. Subscribe to the podcast!Apple | Spotify | YouTube

We love to hear from our listeners. Send us a message.On this episode of Cell & Gene: The Podcast, Christopher McDonald, Global Head of Technical Operations at Kite, a Gilead company, talks to Host Erin Harris about Kite's recent FDA approval of manufacturing process change resulting in reduced median turnaround time for Yescarta. They talk through the most significant steps Kite took to reach this approval, lessons learned from having worked with the FDA, scaling up technologies for cell therapy manufacturing, and more. Subscribe to the podcast!Apple | Spotify | YouTube

Jennifer Klarer from The Dedham Group delves into pricing and value for CGTs, addressing misconceptions and solutions. Topics include time to treatment challenges, securing investment, and payer dynamics. Learn about the importance of early commercial planning and navigating evolving payment models for financial stability.

We love to hear from our listeners. Send us a message.Paul Lammers, M.D., M.Sc., CEO of Triumvira Immunologics joins Cell & Gene: The Podcast to talk to Host Erin Harris about TAC, the company's proprietary T cell Antigen Coupler, which has both autologous and allogeneic approaches. They also discuss targeting relapsed or refractory HER2-positive solid tumors and CLDN18.2-positive solid tumors. And they cover a realistic outlook on the evolution of cancer treatment.Subscribe to the podcast!Apple | Spotify | YouTube

Poseida Therapeutics' CEO Kristin Yarema discusses the challenges of developing off-the-shelf therapies in CGT sector. She highlights the potential progress in allogeneic therapies by 2024. Topics include nanoparticle delivery, allogeneic T cell therapies, strategic investments, manufacturing scale up, and personal plans for 2024.

We love to hear from our listeners. Send us a message.For this third and final episode recorded at ARM's 2023 Meeting on the Mesa, Cell & Gene: The Podcast Host, Erin Harris, sat down with Greg Kunst, president, CEO, and Board member at Aurion Biotech. Listen in as they discuss the cell therapy used to treat corneal endothelial disease and how Greg navigated the event as a first-timer attending Meeting on the Mesa.Subscribe to the podcast!Apple | Spotify | YouTube

We love to hear from our listeners. Send us a message.Vittoria Biotherapeutics’ CEO, Nick Siciliano, joins Erin Harris on this episode of Cell & Gene: The Podcast to discuss the company's mission to expand the applications for CAR-based therapeutics by employing novel cell engineering and gene editing technologies.Subscribe to the podcast!Apple | Spotify | YouTube

Richard Wilson, Senior VP at Astellas, discusses gene therapy deal-making, Astellas' strategic approach post Audentes acquisition, building gene therapy infrastructure, advancements in gene therapy, strategic focus areas like genetic regulation and immuno-oncology, and the importance of partnerships in the cell and gene therapy sector.

We love to hear from our listeners. Send us a message.Ken Mills, CEO, President, and Director at REGENXBIO joins Erin Harris for this episode of Cell & Gene: The Podcast to discuss the company's progress with its Phase I/II Affinity Duchenne trial of RGX-202 for the treatment of Duchenne Muscular Dystrophy. They discuss the future of AAV gene therapy as well as achieving scalability with consistent yield and product purity in gene therapy manufacturing.Subscribe to the podcast!Apple | Spotify | YouTube

We love to hear from our listeners. Send us a message.Alliance for Regenerative Medicine's COO, Rita Johnson-Greene, joined Cell & Gene: The Podcast host, Erin Harris, in person at the 2023 Meeting on the Mesa to discuss this year's event. Johnson-Greene also shared what's ahead for 2024 as the event heads to a new location. They discussed major topics and trends at the event as well as ARM's GROW internship program.Subscribe to the podcast!Apple | Spotify | YouTube